The United States’ Food & Drug Administration is being forced to repeatedly address the same issue with ImmunityBio’s management. Ironically, the biopharma company’s addressable actions don’t offer a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that enrollment and initial follow-up has been completed for the safety ...

ImmunityBio's sales grew 700% in 2025, with fourth-quarter revenue rising 20% quarter over quarter. These excellent results extend an incredible run of good news for the up-and-coming biotech stock.

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Friday after the company announced overall survival results in its QUILT 3.055 study. ImmunityBio said the QUILT 3.055 trial shows median ...

CULVER CITY, Calif.--(BUSINESS WIRE)--The FDA accepted for review a Biologics License Application (BLA) from ImmunityBio, Inc. (NASDAQ: IBRX), for its antibody cytokine fusion protein as a treatment ...

Oral presentation provides update from QUILT-3.032 on durable complete responses to ANKTIVA® plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) with or ...

It wasn't the first time, however. As today's warning letter points out, the FDA also addressed similar issues with wholly owned ImmunityBio subsidiary Altor BioScience, LLC in September of last year ...

ImmunityBio IBRX is building a portfolio of immunotherapies designed to activate both innate and adaptive immunity in cancer and infectious diseases. Its Cancer BioShield platform centers on Anktiva ...

Currently, ImmunityBio's flagship Anktiva drug is approved to treat patients with bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) who have Carcinoma in Situ (CIS ...